Omniscope

Name

Omniscope

Legal name

OMNISCOPE ESPAÑA, S.L.

Website

https://omniscope.ai

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Omniscope is a Barcelona-based TechBio company using AI-powered single-cell immune receptor sequencing to serve biopharma researchers, elite sports organizations, and premium longevity clinics across products osPharma, osSports, and osLifetime.

Ownership category

akta.pro rank

Product category

Immune Profiling Technology

NAICS

Software Publishers (51321), Software Publishers (5132)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)

akta.pro industry

PRIMARYHLAGANAC

Single-Cell & Spatial Omics Services

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

SECONDARYHLAGAJAD

Bioinformatics & Multi-omics Analysis Software

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAAANAF

Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)

Healthcare & Life Sciences/Biotechnology & Biologics/Precision Medicine Solutions

SECONDARYHLAGANAI

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

• Immune profiling technology
• Computational immunology
• Single-cell sequencing
• Biomarker discovery
• Precision medicine

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biopharma Research Services: Services for biopharma companies including immune monitoring, biomarker discovery, patient stratification, and clinical trial support. Revenue derived from project-based contracts and ongoing research collaborations.
2. osPharma Platform (OS-IMT, OS-MRD): Products in immunotherapy monitoring and minimal residual disease patient monitoring across different cancer types. Subscription-based access to immune profiling analysis platform.
3. osLifetime Consumer Health: Direct-to-consumer and clinic-partner distributed immune age and healthspan optimization services. Consumers access through partner clinics (Barna Clinic, Sand Clinic, AYUN) or directly via platform.
4. osSports Performance Platform: AI-powered immune tracking for athletes and sports organizations to optimize performance, recovery, and injury prevention. Revenue from team/organization subscriptions.
5. EU Research Project Funding: Horizon Europe and Marie Sklodowska-Curie Actions funded research projects where Omniscope participates as industrial partner (EPIVINF: EUR 1.5M allocation, LIFELUNG, RESPIRE-EXCEL, BAXERNA 2.0, SIGNATURE, YELLOW4FLAVI).

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Omniscope operates an AI-powered immune profiling platform that combines proprietary single-cell T cell receptor (TCR) and B cell receptor (BCR) sequencing with computational immunology analysis. It sells three market-facing software platforms — osPharma for biopharma research and clinical trial immune monitoring, osSports for athletic performance and recovery, and osLifetime for personal healthspan and immune age tracking — plus the Immune Portal (osIP) public analytics platform.

Product overview

Omniscope is a techbio company operating a platform-plus-modules architecture centered on AI-powered immune profiling technology. The core technology combines proprietary single-cell TCR/BCR sequencing (osT) with multi-omics analysis and computational models to decode the adaptive immune system. The platform comprises three market-facing products: osPharma for pharmaceutical research and drug development, osSports for athletic performance optimization, and osLifetime for healthspan and longevity applications. The Immune Portal (osIP) provides public access to analytical datasets. All products leverage shared technology layers including the osT sequencing platform, the Model of Age framework, and AI-driven biomarker discovery capabilities. The company was founded in 2020 and operates global operations with laboratory facilities in Barcelona, Spain.

Differentiator

Problem solved

Functional benefit

Brands

• osSports: AI-powered platform for decoding the immune system to optimize athletic performance and recovery, partnered with FC Barcelona's Innovation Hub.
• osLifetime
• osPharma
• osIP (Immune Portal)

Products and services

• osPharma A platform for biopharma companies, academic researchers, and clinical consortia to decode immune responses, discover biomarkers, perform patient stratification, and support immunotherapy and vaccine development through immune repertoire analytics.
• osSports An AI-powered platform that decodes an athlete's immune system to optimize performance, recovery, and injury prevention by tracking inflammation, immune age, and adaptation dynamics. Distributed through partnerships with elite sports organizations such as FC Barcelona and RAFA Racing Club.
• osLifetime A healthspan optimization platform that quantifies immune system aging through metrics including Immune Age, Inflammaging, Protection Score, Senescence, Telomere Length, and Epigenetic Clock, distributed to individual consumers via partner clinics (Barna Clinic+, Sand Clinic, AYUN).
• Immune Portal (osIP) A public-facing data analytics and visualization portal providing access to Omniscope's immune repertoire datasets and analytical tools for academic researchers and developers.

Quantifiable outcome

• Single-cell resolution profiling of up to 1,000,000 T cells
• +3 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core.

• FC Barcelona / Barca Innovation HubcoreStrategic or Co-development Partner · 8 January 2025Omniscope partners with FC Barcelona's Barca Innovation Hub to deploy osSports immune profiling technology for athlete performance optimization. The partnership enables immune system analysis to predict fatigue, prevent injuries, and extend player careers. Featured in multiple media outlets including BBC Sport, National Geographic, and The Athletic (NYT).
• Google CloudcoreTechnology or IntegrationGoogle Cloud partnership for cloud infrastructure supporting Omniscope's computational immunology platform and data processing capabilities.
• GSKcoreStrategic or Co-development PartnerStrategic partnership with GSK, one of the world's largest pharmaceutical companies, for immune profiling applications in drug development and healthcare.
• INSERMcoreStrategic or Co-development PartnerPartnership with Institut National de la Sante Et de la Reserche Medicale (INSERM), France's national institute for health research, across multiple EU-funded projects including YELLOW4FLAVI.
• Centro Nacional de Analisis Genomico (CNAG)coreStrategic or Co-development PartnerCNAG is one of Europe's largest genome centers where CSO Prof. Holger Heyn leads the Single Cell Genomics Group. Deep research partnership for sequencing and analysis capabilities.
• LifeLUNG Consortium PartnerscoreStrategic or Co-development Partner12-partner EU consortium including KU Leuven, Hospital Foch, Medical University Vienna, University of Tuebingen, Lund University, Miltenyi Biotec, Antleron, UCL, Aarhus University, Fundacion Hitt, UMC Utrecht for lung transplantation research.
• BAXERNA 2.0 ConsortiumcoreStrategic or Co-development PartnerMulti-partner EU project for novel mRNA vaccine development against bacterial pathogens including Mycobacterium tuberculosis. Partners include VIB, University of Gent, Karolinska Institutet, Institut Pasteur, Radboud UMC, RheaVita, ULB, Univercells, VUB, Vaccine Formulation Institute.
• barnaclinic+coreChannel Partner/ Reseller/ DistributorPartnership with barnaclinic+ (integrated into Grup Hospital Clinic de Barcelona, Spain's top hospital) to deliver AI-driven immune decoding for sports medicine and performance health to active individuals.
• AYUN CliniccoreChannel Partner/ Reseller/ DistributorPartnership with AYUN Clinic (Switzerland) to offer osLifetime cellular avatar and longevity services, combining science with longevity-focused healthcare delivery.
• Sand CliniccoreChannel Partner/ Reseller/ DistributorPartnership with Sand Clinic (Sweden) for osLifetime distribution, providing personalized medicine, health coaching, nutrition, physiotherapy, and psychology services.
• Barna Clinic+coreChannel Partner/ Reseller/ DistributorPartnership with Barna Clinic+ for osLifetime availability in Spain, integrated with Grup Hospital Clinic de Barcelona's healthcare ecosystem.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Adaptive Biotechnologies: Adaptive Biotechnologies is the closest direct competitor, commercializing immune repertoire sequencing (TCR/BCR) for drug discovery, clinical trials, and immune monitoring. Both companies target biopharma R&D with adaptive immune receptor repertoire (AIRR) profiling, making Adaptive the most directly comparable public-market peer.
• Personalis: Personalis is a cancer genomics company offering tumor-informed molecular profiling and immuno-oncology biomarker services. Like Omniscope, it sells into biopharma for patient stratification and clinical trial immune monitoring, and both companies focus on immuno-oncology applications of next-generation sequencing.
• SOPHiA Genetics: SOPHiA Genetics applies AI to multi-omics data interpretation for clinical and biopharma customers, similar to Omniscope's AI-driven bioinformatics and biomarker interpretation layer. Both companies package algorithmic analysis on top of sequencing data for clinical and research use cases.

Broad incumbents

• 10x Genomics: 10x Genomics provides single-cell sequencing platforms (Chromium, Xenium) widely used in TCR/BCR profiling. Omniscope's CEO Vijay Vaswani previously held a senior role there. They are a tooling and platform incumbent whose products underpin much of Omniscope's own sequencing workflow.
• Illumina: Illumina dominates sequencing instrumentation used by virtually all immune profiling players including Omniscope. CEO Vijay Vaswani also previously held a leadership role at Illumina, and Illumina's installed base and NovaSeq/X platforms are the de facto upstream infrastructure for Omniscope's analyses.
• Tempus AI: Tempus AI combines multi-omics sequencing with AI to enable precision medicine across oncology, cardiology, and neurology. Omniscope's biomarker discovery and patient stratification focus in pharma overlaps with Tempus's biopharma services, though Tempus operates at much larger scale.
• NeoGenomics: NeoGenomics provides oncology-focused clinical and research laboratory services including molecular and immuno-oncology testing. It overlaps with Omniscope on the pharma/biopharma R&D services side, particularly around clinical trial immune monitoring and biomarker work.
• Becton, Dickinson and Company (BD Biosciences): BD offers flow cytometry, single-cell multi-omics tools (BD FACSDiscover), and reagents used widely in immunology research. It is an incumbent in adjacent immune phenotyping technologies and competes indirectly with Omniscope for immunology research budgets.

Emerging players

• ImmunoScape: ImmunoScape is a deep-immune profiling company focused on TCR-based analytics for immunotherapy development and immune monitoring. It overlaps directly with Omniscope's osPharma/OS-IMT use cases and is a credible emerging competitor in cancer immunotherapy monitoring.

Regional players

• Eurofins Genomics: Eurofins Genomics is a large European genomics services provider offering sequencing, genotyping, and bioinformatics services. It is comparable to Omniscope on the lab services dimension and operates in overlapping European academic and clinical research customer bases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/OmniscopeAI
• LinkedInlinkedin.com/company/omniscopeai

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omniscope